PT  - JOURNAL ARTICLE
AU  - Francisco Javier Callejas Gonzalez
AU  - Javier Cruz Ruiz
AU  - Raul Godoy Mayoral
AU  - Ana Isabel Tornero Molina
AU  - Sergio Garía Castillo
AU  - Mariela Plenc Ziegler
AU  - Abel Martinez Garcia
AU  - Juan Pastrana Calderon
AU  - Rafaela Sanchez Simon-Talero
AU  - Juan Carlos Ceballos Romero
TI  - Results in a tobacco consulting room in Albacete University Hospital in 2009
DP  - 2012 Sep 01
TA  - European Respiratory Journal
PG  - P4031
VI  - 40
IP  - Suppl 56
4099  - http://erj.ersjournals.com/content/40/Suppl_56/P4031.short
4100  - http://erj.ersjournals.com/content/40/Suppl_56/P4031.full
SO  - Eur Respir J2012 Sep 01; 40
AB  - Introduction: Results in a Tobacco Consulting Room in 2009. Material and Methods: Retrospective descriptive analysis of the results obtained from patients who were attended in a Tobacco Consulting Room from 1 January to 31 December 2009 and subsequent follow-up to complete a year. Results: 291 of 428 patients (51.2% male), mean age 46 years and mean cigarettes/day 27.5. Moderate-severe nicotine dependence (Fagerström 6.8) and high motivation (Richmond 8.11). Respiratory comorbidity: 12.1% COPD, 7.6% asthma, 11% OSAHS and 0.3% HOT; Cardiac: Ischemic Cardiopaty, 4.8% and Arrhytmia, 2.1%; CVRF: 30.9% dyslipidemia, 19.9% HT and 9.3% DM. 42.6% global psychiatric comorbidity, 37.5% depression and/or anxiety and 13.4% alcoholism. 22% without treatment, 44.6% NRT, 13.1% bupropion and 20.3% varenicline. Those who were treated pharmacologically, although non statistical significance, greater number of days of abstinence among who used varenicline than NRT or bupropion (59.3 vs. 46.7). 7.2% never got more than 24 hours abstinence. Overall of the 291 patients, treatment success (one year without smoking) in 31 (10.7%); Percentage rises to 24.8% if we don't consider those who didn't attend the second consultation. Conclusions: 1. 70.8% didn't start treatment (32% and 57%, first and second appointment respectively). 2. Moderate-severe nicotine dependence and high motivation. 3. Severe comorbidity, especially psychiatric, respiratory and CVRF. 4. Greater number of days of abstinence among who used varenicline than NRT or bupropion (59.3 vs. 46.7). 5. 7.2% never got more than 24 hours abstinence. 6. Overall treatment success 10.7%, amounting to 24.8% excluding those who don't attend the second consultation.